itral stenosis (MS) is known to comprise 2 stenotic lesions: the mitral valve itself and pulmonary arteriolar stenosis, anatomically or functionally. 1,2 MS initially produces pulmonary venous hypertension and subsequently, pulmonary arterial hypertension develops because of the combined effect of back pressure, pulmonary arteriolar constriction and obliterative changes in the pulmonary vascular bed. 1,2 Pulmonary vascular resistance (PVR), representing pre-capillary resistance, reflects pulmonary arteriolar stenosis or pulmonary vascular reactivity, and is a major determinant of exercise capacity and right ventricular (RV) afterload in MS. 3 Net-atrioventricular compliance (Cn), a determinant of pressure decay across the stenotic mitral valve, is related to post-capillary resistance and is also a major determinant of inappropriate elevation of pulmonary arterial pressure during exercise. 4 could be related to increased PVR or direct RV involvement in rheumatic heart disease. 5 RV function significantly affects symptoms, exercise capacity, peri-operative mortality and postoperative results; 6 however, measurement of PVR or RV function has limitations because of the invasiveness of the procedure and the geometric complexity of the RV. Development of the Doppler technique has enabled measurement of new parameters representing PVR and RV function, 7,8 and the major advantage of these Doppler-derived parameters is that they are highly reproducible. Based on this, we aimed to determine if echo-Doppler derived PVR (PVRecho), Cn and peak systolic tricuspid annular velocity (Sa) as parameters of RV function are relevant in predicting the cardiopulmonary exercise (CPX) capacity of patients with MS.
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Methods

Study Population
Thirty-two consecutive patients (25 females, age 52.0± 9.4 years) with moderate or severe MS (mitral valve area (MVA) by 2-dimensional (2D) planimetry: 0.7-1.5 cm 2 ) were studied. Exclusion criteria included patients with left ventricular (LV) systolic dysfunction (ejection fraction (EF) <50%), mitral regurgitation more than grade I, history of underlyng ischemic heart disease or exercise-induced ST segment change on 12-lead electrocardiogram (ECG) suggeting myocardial ischemia, valvular heart disease other than secondary tricuspid regurgitation, congenital heart disease, and chronic pulmonary disease. The study protocol was approved by the institutional review board and all the patients gave informed consent.
Resting Echo-Doppler Measurements
All patients underwent a complete standard echocardiographic examination. The transmitral mean diastolic pressure gradients (MDPG) were obtained from the continuouswave Doppler signal of mitral flow velocity. Stroke volume (SV) was calculated as LV outflow tract (OT) area multiplied by the time-velocity integral (TVI) at the LVOT. OT area was determined as D 2 /4, where D is its diameter measured from a zoomed systolic freeze-frame in the parasternal long-axis view. Cardiac output (CO) was calculated as a product of SV and heart rate (HR). With the continuity equation, the effective orifice area of the mitral valve (EOA) was calculated as SV divided by mitral TVI. 9, 10 Cn was calculated from the deceleration rate (dV/dt) (Fig 1) of the mitral velocity profile (E-wave downslope) and EOA as 1,270× (EOA/dV/dt) and the result is expressed in milliliters per millimeter of mercury. 4 MVA was also measured by 2D planimetry method. 11 The left atrial volume index (LAVI) was calculated by the prolate ellipsoid method. 12 The TVIRVOT (cm) was obtained by placing a 1-to 2-mm pulsed wave Doppler sample volume in the proximal RVOT just within the pulmonary valve when imaged from the parasternal short-axis view. Continuous wave Doppler was used to determine the peak tricuspid regurgitant velocity (TRV) (m/s). The highest velocity obtained from multiple views was used. The 10× (peak TRV/TVIRVOT) +0.16 was then calculated and used as PVRecho (WU). 7 To measure the systolic tricuspid annular velocities, the spectral pulsed Doppler was adjusted to obtain a Nyquist limit of 20-30 cm/s. We used minimal gain to ensure clear-and welldefined pulsed Doppler tissue imaging wave borders. Tricuspid annular tissue velocity was obtained in the apical 4-chamber view. Care was taken to use an ultrasound beam parallel to the direction of the tricuspid motion. To exclude the effect of respiration, measurements were acquired during end-expiratory apnea. For the evaluation of peak systolic velocity, the initial peak occurring during isovolumic contraction was ignored (Fig 1) . Measurements during 5 consecutive cardiac cycles representing the mean HR were averaged and used for further calculations. 13 
Exercise Echocardiography and Respiratory Gas Analysis
All patients underwent symptom-limited exercise tests on a supine bicycle ergometer (Medical Positioning, Inc, Kansas City, MO, USA) with simultaneous respiratory gas analysis and blood pressure recording. The CPX test was performed immediately after echocardiographic examination (Vivid 7 ultrasound machine, GE Medical Systems). Exercise began with 25 W after a 1-mine unload phase, followed by a ramp protocol with increments of 25 W every 3 min. At each stage, HR, transmitral and transtricuspid continuous wave Doppler, and pulsed wave Doppler of the LVOT and RVOT were obtained and MDPG, peak TRV, TVILVOT and TVIRVOT were measured using a post-processing program (EchoPAC, GE Medical Systems). Using these parameters, CO and PVRecho were calculated. Measurements were performed by 2 independent investigators. Be- cause the area of the LVOT and the RVOT has been shown to remain constant during exercise, 13, 14 the resting values were used to calculate both rest and exercise SV. Oxygen uptake, CO2 production and minute ventilation were measured using a breath-by-breath gas analysis (Medical Graphics, St Paul, MN, USA). A 12-lead ECG was continuously registered to exclude significant myocardial ischemia. Blood pressure was recorded every 3 min by cuff sphygmomanometer. Peak oxygen consumption (peak V
• O2) was defined as the mean of the highest values obtained over the last 10 s of exercise. Minute ventilation, oxygen consumption, and CO2 production were calculated online every 10 s with the use of a standard inert gas dilution technique. Predicted values for peak oxygen consumption (%V • O2 peak) were calculated from a gender-specific regression equation incorporating age, height, and weight. 15 
Statistical Analysis
Results are presented as mean value ± standard deviation. Interobserver variability was calculated as the standard deviation of the differences between the measurements made by 2 independent observers as a percentage of the average value. Comparison of several parameters between patients with normal sinus rhythm (NSR) and patients with atrial fibrillation (AF) was performed with Mann-Whitney test and Fisher's exact test. Differences between rest and peak exercise values were tested for significance by use of a paired 2-samples t-test. Univariate and multiple stepwise linear regression analyses were generated between echo-Doppler parameters and CPX parameters. A receiver-operating characteristic analysis was used to obtain the optimal cutoff Sa/PVRecho and Cn· (Sa/PVRecho) values for predicting higher than 65% of %V • O2 peak. We used the SPSS 13.0 statistical package (SPSS Inc, Chicago, IL, USA) with p-values <0.05 considered as statistically significant.
Results
Baseline Characteristics
Of the 32 subjects, 17 (53.1%) had AF and 25 patients (78.1%) were female. The patients' clinical and resting echoDoppler characteristics according to baseline rhythm are presented in Table 1 . Interobserver variability of PVRecho, Sa, Cn was 4% and 3% and 6%, respectively. The MVA measured by 2D planimetry method was 1.3±0.2 cm 2 , peak TRV was 2.63±0.37 m/s, TVIRVOT was 14.48±3.03 cm and 
CPX and Echo-Doppler Parameters
There were no significant adverse outcomes during the CPX test and the results and those of the echo-Doppler parameters at peak exercise are presented in Table 2 . The mean exercise duration was 428.0±148.9 s. At peak exercise, mean systolic blood pressure was 156.4±25.0 mmHg and mean HR was 135.7±22.6 beats/min. During exercise, peak TRV, MDPG and CO increased to 3.82±0.51 m/s, 23.57±9.15 mmHg and 7,501.3±1,934.8 ml/min, respectively (Fig 2) . However, the exercise response of CO was more heterogeneous than other parameters. Peak V
• O2 was 18.1±5.3 ml·kg -1 ·min -1 (range 10.7-31.7), %V
• O2 peak was 65.9±14.1% (range 42.0-98.0) and V • E/V • CO2 at anaerobic threshold (AT) was 37.2±24.7 (range 32.1-46.9).
Determinants of CPX Capacity
Doppler-derived CO at peak exercise correlated well with peak V
• O2 (r=0.572, p=0.001). Resting PVRecho correlated inversely with resting Sa (r=-0.371, p=0.037). The decrement in resting Cn was significantly related with decrease in %V
• O2 peak (r=0.469, p= 0.007). Increase in resting PVRecho and decrease in resting Sa were significantly associated with impairment of %V
• O2 peak (r=-0.416, p=0.018 for PVRecho and r=0.433, p=0.013 for Sa) (Fig 3) . Moreover, PVRecho at peak exercise correlated significantly with decrease of %V
• O2 peak (r=-0.482, p=0.005). LAVI also inversely correlated with %V
• O2 peak, but did not reach the statistical significances (r=-0.318, p=0.077). Percentage of V
• O2 peak of patients with AF was lower than that of patients with NSR (58.8±9.9% vs 73.9± 14.2%, p=0.001), as a decrease of Sa (9.02±1.95 vs 11.0± 1.22 cm, p=0.002) (Tables 1,2 ). Based on these results, we combined the indices that represented total pulmonary resistance as PVRecho/Cn, and overall RV function incorporated with afterload as Sa/PVRecho. We discovered these new indices of total pulmonary resistance (PVRecho/Cn) (r=-0.489, p=0.005) and RV function (Sa/PVRecho) (r= 0.500, p=0.004) correlated more significantly with %V • O2 peak. By combing these left and right chamber parameters as Cn· (Sa/PVRecho), which determines RV function and pre-and post-capillary resistance, we could further elevate the predictive accuracy for exercise capacity (r=0.572, p=0.001) (Fig 4) . In subgroup analysis by underlying rhythm, these correlations were maintained, but the degree of correlation was weak in patients with AF (Sa/PVRecho, r=0.773, p<0.001 in NSR and r=0.449, p=0.071 in AF; Cn· (Sa/PVRecho), r=0.670, p=0.006 in NSR and r=0.553, p= 0.021 in AF). In multiple stepwise linear regression analysis, the right chamber parameter of Sa/PVRecho ( =0.349, p=0.031) independently correlated with %V
• O2 peak after adjusting for left-side parameters, such as Cn, LAVI, MVA, MDPG, and the presence of AF (Table 3) . However, the correlation between Sa/PVRecho and V
• E/V • CO2 at AT did not reach statistical significance (r=-0.385, p=0.085). According to these results, we successfully obtained optimal cutoff values of Sa/PVRecho and Cn· (Sa/PVRecho) for predicting %V
• O2 peak higher than 65% as 4.81 (sensitivity of 71% and specificity of 67%) and 22.9 (sensitivity of 71% and specificity of 87%), respectively.
Discussion
The principal finding of this study is that Sa and PVRecho are significantly related with exercise capacity. Therefor, their derivative as Sa/PVRecho, reflecting RV function and the RV loading state, could be a predictor of exercise capacity independent of left-side chamber parameters and the presence of AF.
Inappropriate and excessive increase of pulmonary arterial pressure beyond changes in the left atrial pressure is known to be a major exercise-limiting factor in patients with MS. 16 Simple backward transmission of increased transmitral gradients cannot explain the entire increase in pulmonary artery pressure. Decrease of left atrial compli- ance is one of the possible mechanisms that lead to the excessive increase of pulmonary arterial pressure. 17 Another possibility is the occurrence of pulmonary arteriolar vasoconstriction because of the development of pulmonary edema and alveolar hypoxia with exercise. 18 The level of oxygen saturation of the pulmonary arterial blood is reported to be the most significant factor in determining the exercise capacity in patients with valvular heart disease and chronic obstructive pulmonary disease. 19 Respiratory gas analysis is an extremely useful method of detecting this pathologic response. The results of our study also show that increased PVRecho and decreased Cn are significantly associated with decreased %V • O2 peak, which suggests that increased resting PVRecho is a useful predictor of pulmonary vascular response and, consequently, inappropriate ventilatory response to exercise. Besides, in patients with MS, total pulmonary resistance, which is the resistance to blood flow from the pulmonary artery to the left ventricle in diastole, is more important. It represents the sum of pre-and post-capillary resistance. Based on our results, we arrived at PVRecho/Cn as the index of total pulmonary resistance, in which PVRecho represents pre-capillary resistance and 1/Cn reflects post-capillary resistance. We found that this index is more related to exercise capacity.
The primary function of the RV free wall is to move the atrioventricular valve ring toward the apex by contraction of longitudinal myocardial fibers. 20 Based on this concept, tricuspid annular longitudinal velocity measured by tissue Doppler imaging technique has been validated as an index of RV systolic function by comparing radionuclide ventriculography in patients with heart failure. 8 A significant advantage of these Doppler-derived parameters is that they are highly reproducible. In our study, Sa varied from 6.8 to 13.1 cm/s and correlated weakly with PVRecho, which implies that Sa can be affected by other mechanisms, as well such as by direct myocardial involvement of rheumatic processes besides RV afterload. In patients with heart failure, RVEF at rest has been reported to correlate with peak V
• O2, especially %V • O2 peak. 21, 22 Moreover, RVEF has been shown to be superior to LVEF in predicting exercise capacity. 22 A recent study by Ghio et al showed that the combination of invasively measured RVEF and pulmonary arterial pressure is critically important in the prediction of prognosis in patients with advanced heart failure. 23 Based on the results of previous study and our results, we combined Sa and PVRehco as Sa/PVRecho, reflecting RV contractile function, adjusting for its afterload. Interestingly, we discovered that this new index correlated more significantly with exercise capacity and it could be an independent predictor of exercise capacity after adjusting for the presence of AF and left-chamber parameters such as Cn, LAVI, MVA and MDPG. Finally, by incorporating left-and rightchamber parameters, which determine exercise capacity, we could further improve the accuracy of prediction.
Our study also demonstrated that the development of AF was significantly associated with lower exercise capacity, despite similar MVA and MDPG, compared with patients with NSR. Higher LAVI and lower RV functional indices in the AF group might be related to lower exercise capacity. Despite not being proven in this study, loss of atrial contraction and decreased pulmonary venous systolic flow might be another possible explanation for the more impaired exercise capacity in patients with AF. 24 However, when controlling the effect of AF, Sa/PVR was significantly related with exercise capacity. Moreover, these correlations were maintained in the subgroup analysis according to baseline rhythm. Because of the small number of subjects, possible variability of the measured value, and more complex factors contributing to exercise capacity, the accuracy of prediction was lower in patients with AF.
When we define the grade of MS, we classically consider MVA or MDPG. However, the guidelines for surgery or balloon valvuloplasty are made based on the patient's symptoms or exercise capacity. Even in patients with the same grade of MS based on MVA or MDPG, there might be heterogeneous patients in terms of exercise capacity or symptoms, as in the results of this study. Moreover, the patient's symptoms are very subjective and all the patients cannot undergo CPX; measurement of a resting predictor of exercise capacity, especially non-invasively, is important in the triage of patients. Our results suggest that RV function and PVR have independent roles, not only passively determined by backward pressure transmission, especially when determining the ventilatory response to exercise. Therefore, it might be helpful in the triage the patients and may serve as a new guideline for early interventional treatment, such as percutaneous mitral valvuloplasty or mitral valve replacement surgery.
Study Limitations
First, 53% of the present subjects had AF. Although measurements during 5 consecutive cardiac cycles representing the mean HR were averaged and used for further calculations, there could be higher variability in the value of each parameter in the subjects with AF compared with those in NSR. It might partially contribute to weak correlations between applied parameters in patients with AF compared with patients with NSR. Second, we could not invasively validate PVRecho/Cn as an index of total pulmonary resistance. We only proposed this index conceptually and it needs to be validated in the future.
